Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Breast Neoplasms 881Neoplasms 668Prostatic Neoplasms 455Lung Neoplasms 368Colorectal Neoplasms 335Carcinoma, Non-Small-Cell Lung 320Leukemia, Myeloid, Acute 257Pancreatic Neoplasms 224Brain Neoplasms 210Multiple Myeloma 204Neoplasm Metastasis 201Carcinoma, Hepatocellular 184Head and Neck Neoplasms 183Glioblastoma 170Precursor Cell Lymphoblastic Leukemia-Lymphoma 169Melanoma 159Ovarian Neoplasms 158Squamous Cell Carcinoma of Head and Neck 152Recurrence 139Rectal Neoplasms 137Hematologic Neoplasms 130Sarcoma 126Uterine Cervical Neoplasms 124Stomach Neoplasms 118Carcinoma, Renal Cell 118Triple Negative Breast Neoplasms 116Glioma 116Motor Activity 105Urinary Bladder Neoplasms 100Myelodysplastic Syndromes 99

Interventions

darolutamide 1bicalutamide 1abemaciclib 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Bulbo-Spinal Atrophy, X-Linked × 90 days × Clear all
NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT06365788 2026-04-01

ABBICAR

Universitaire Ziekenhuizen KU Leuven

Phase 2 Recruiting
53 enrolled
Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡